XLRN Acceleron Pharma Inc.

+0.36  (+1%)
Previous Close 44.16
Open 44.2
Price To Book 8.01
Market Cap 2336978877
Shares 52,492,787
Volume 115,246
Short Ratio
Av. Daily Volume 535,778

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1H 2020.
Pulmonary arterial hypertension (PAH)
Phase 3 trial initiated - noted October 30, 2018.
Luspatercept - COMMANDS
First-line, lower-risk Myelodysplastic syndromes (MDS)
Phase 2 data 2H 2019.
Phase 2 Part 2 preliminary data due by the end of 2019.
Charcot-Marie-Tooth disease (CMT)
BLA filing due April 2019.
Luspatercept - BELIEVE
b -thalassemia
BLA filing due April 2019.
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 2 updated data at ASH 2016.
Low or intermediate-risk MDS patients who are erythropoiesis-stimulating agent (ESA) naïve or ring sideroblast negative (RS-)
Phase 2 Part 2 data due 2H 2019.
Facioscapulohumeral muscular dystrophy
Phase 2 data released June 12, 2017 - primary endpoint not met.
Dalantercept - DART Study
Renal Cell Carcinoma (RCC) - cancer
Phase 2 updated data at ASCO June 2018. 55% achieved a clinically meaningful erythroid improvement.
Luspatercept Extension Study - PACE-MDS
Myelodysplastic Syndromes
Preliminary results due 1H 2019.
Healthy volunteers
Phase 2 data due 2020.
Luspatercept - BEYOND
Non-transfusion-dependent beta-thalassemia

Latest News

  1. Edited Transcript of XLRN earnings conference call or presentation 27-Feb-19 10:00pm GMT
  2. Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Charcot-Marie-Tooth Disease
  3. Acceleron Pharma Inc. (NASDAQ:XLRN): The Best Of Both Worlds
  4. Acceleron Pharma (XLRN) Q4 2018 Earnings Conference Call Transcript
  5. Acceleron Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
  6. Acceleron Pharma Is Ready to Rally Ahead of Earnings
  7. Is Acceleron Pharma a Buy?
  8. Earnings Preview: Acceleron Pharma (XLRN) Q4 Earnings Expected to Decline
  9. Acceleron to Webcast Fourth Quarter and Full Year 2018 Operating and Financial Results on February 27, 2019
  10. Acceleron to Present at Two Upcoming Healthcare Investor Conferences
  11. Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y
  12. Is a Beat in the Cards for Celgene (CELG) in Q4 Earnings?
  13. Celgene Buys More of This Biotech Stock
  14. Consolidated Research: 2019 Summary Expectations for Marathon Petroleum, AMC Entertainment, JetBlue Airways, Acceleron Pharma, Natera, and AquaVenture — Fundamental Analysis, Key Performance Indications
  15. Acceleron Announces Pricing of Public Offering of Common Stock
  16. Acceleron Announces Proposed Public Offering of Common Stock
  17. Acceleron Announces Publication of Luspatercept Phase 2 Beta-Thalassemia Study Results in Blood
  18. Celgene (CELG) Provides Guidance for 2019, Updates Pipeline
  19. Here's Why Acceleron Pharma Fell 17.7% in December
  20. Acceleron to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference